Table 2. Patient characteristics at study entry by treatment arm.
| Initial ART includes: | |||
| Variable | Stavudine | Zidovudine | p-value1 |
| Number (patient years follow-up) | 1853 (2460) | 209 (287) | |
| Age, years Mean (SD) | 35.7 (8.3) | 37.8 (9.6) | <.001 |
| Patient years of follow up Mean (SD) | 1.3 (0.7) | 1.4 (0.6) | <.001 |
| Female n (%) | 1078 (58.2) | 188 (90) | <.001 |
| BMI (kg/m2) Median (IQR) | 22 (19, 24) | 30 (28, 33) | <.001 |
| CD4 (cells/mm3) Median (IQR) | 75 (27, 138) | 129 (61, 172) | <.001 |
| Creatinine (mg/dL) Median (IQR) | 1.0 (0.4) | 0.9 (0.3) | .21 |
| ALT (IU/L) Median (IQR) | 24 (18, 35) | 23 (17, 32) | .27 |
| Albumin (g/L) Median (IQR) | 31.2 (7.3) | 34.9 (5.3) | <.001 |
| Hemoglobin (g/dL) Median (IQR) | 10.8 (2.1) | 11.6 (1.3) | <.001 |
1
Chi-square test was used for categorical variables, T-test for continuous where mean and standard deviation reported, and Wilcoxon rank sum where median and IQR reported.